A research collaboration between the Faculty of Biochemistry and Molecular Medicine at the University of Oulu, Finland, the University of Innsbruck, Austria, and Florida Tech, USA, explored the ...
A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow.